Josephine Zhang
Overview
Explore the profile of Josephine Zhang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lemaitre L, Adeniji N, Suresh A, Reguram R, Zhang J, Park J, et al.
Nat Cancer
. 2024 Sep;
5(10):1534-1556.
PMID: 39304772
Hepatocellular carcinoma (HCC) frequently recurs from minimal residual disease (MRD), which persists after therapy. Here, we identified mechanisms of persistence of residual tumor cells using post-chemoembolization human HCC (n = ...
2.
Lehrich B, Zhang J, Monga S, Dhanasekaran R
J Hepatol
. 2023 Dec;
80(3):515-530.
PMID: 38104635
The diagnosis and management of hepatocellular carcinoma (HCC) have improved significantly in recent years. With the introduction of immunotherapy-based combination therapy, there has been a notable expansion in treatment options...
3.
Sengupta S, Zhang J, Reed M, Yu J, Kim A, Boronina T, et al.
J Exp Med
. 2023 Apr;
220(7).
PMID: 37058141
Distinct CD4+ T cell epitopes have been associated with spontaneous control of HIV-1 replication, but analysis of antigen-dependent factors that influence epitope selection is lacking. To examine these factors, we...
4.
Dhanasekaran R, Hansen A, Park J, Lemaitre L, Lai I, Adeniji N, et al.
Cancer Res
. 2022 Dec;
83(4):626-640.
PMID: 36525476
Significance: Macrophage-mediated immune evasion is a therapeutic vulnerability of MYC-driven cancers, which has implications for prioritizing MYC-driven hepatocellular carcinoma for combination immunotherapy.
5.
Zhang J, Siller-Farfan J
Immunother Adv
. 2022 Oct;
2(1):ltac014.
PMID: 36284838
Glioblastoma multiforme (GBM) is the most malignant form of cancer in the central nervous system; even with treatment, it has a 5-year survival rate of 7.2%. The adoptive cell transfer...
6.
Sengupta S, Board N, Wu F, Moskovljevic M, Douglass J, Zhang J, et al.
Proc Natl Acad Sci U S A
. 2022 Apr;
119(15):e2123406119.
PMID: 35394875
HIV-1 infection is incurable due to the persistence of the virus in a latent reservoir of resting memory CD4+ T cells. “Shock-and-kill” approaches that seek to induce HIV-1 gene expression,...